KLKB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Trifluoroacetic Acid (SCHEMBL393662)	0.72	20/20
SCHEMBL388944	0.54	20/20
SCHEMBL369754	0.52	20/20
SCHEMBL393390	0.52	20/20
SCHEMBL393391	0.52	20/20
SCHEMBL393392	0.52	20/20
SCHEMBL393831	0.92	19/20
SCHEMBL392450	0.81	19/20
SCHEMBL392451	0.81	19/20
SCHEMBL392750	0.81	19/20
SCHEMBL392751	0.81	19/20
SCHEMBL393092	0.81	19/20
SCHEMBL393093	0.81	19/20
SCHEMBL392366	0.77	19/20
SCHEMBL392367	0.77	19/20
SCHEMBL390122	0.68	19/20
SCHEMBL390123	0.68	19/20
SCHEMBL391743	0.68	19/20
SCHEMBL391744	0.68	19/20
SCHEMBL393112	0.66	19/20

Clinical trials — most relevant to KLKB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein	PHASE4	UNKNOWN
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA	PHASE1/PHASE2	RECRUITING
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer	PHASE2	COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	PHASE2	COMPLETED
Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)	PHASE2	RECRUITING
Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists	PHASE2	COMPLETED
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME	PHASE1	COMPLETED
Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074	PHASE1	COMPLETED
A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects	PHASE1	COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
Stockholm3 Validation Study in a Multi-Ethnic Cohort	nan	COMPLETED
The Contact Activation System and Ulcerative Colitis	nan	COMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion	nan	RECRUITING
Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism	nan	COMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer	nan	COMPLETED
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland	nan	UNKNOWN
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.	nan	COMPLETED
Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer	nan	UNKNOWN
Hemostasis in Sickle Cell Disease--Infancy to Adulthood	nan	COMPLETED
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy	nan	COMPLETED
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)	nan	RECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Salivary Cytokines as Biomarker for Oral Health	nan	COMPLETED
Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery	nan	RECRUITING
Transformative Research in Diabetic Nephropathy	nan	RECRUITING
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease	nan	COMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
A Study of Novel Biomarkers of Kidney Dysfunction at Liver Transplant	nan	COMPLETED
Markers and Mechanisms of Vascular Disease in Type II Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KLKB1 binder may also engage these)

Protein	Name	Similarity
P26262	—	1.000	P26262 →
P14272	—	1.000	P14272 →
Q91Y47	—	1.000	Q91Y47 →
Q2KJ63	—	1.000	Q2KJ63 →
F11	Coagulation factor XI	1.000	landscape →
Q5NTB3	—	0.997	Q5NTB3 →
Q58L93	—	0.995	Q58L93 →
P11214	—	0.995	P11214 →
P17945	—	0.995	P17945 →
P79953	—	0.995	P79953 →
Q7RTY8	—	0.994	Q7RTY8 →
P49150	—	0.994	P49150 →
Q90WD8	—	0.993	Q90WD8 →
Q86T26	—	0.993	Q86T26 →
Q08048	—	0.993	Q08048 →
P86091	—	0.992	P86091 →
Q58L94	—	0.992	Q58L94 →
TMPRSS15	Enteropeptidase	0.992	landscape →
P00741	—	0.992	P00741 →
Q9JIQ8	—	0.991	Q9JIQ8 →
Q14C59	—	0.991	Q14C59 →
P98119	—	0.990	P98119 →
Q6ZMR5	—	0.990	Q6ZMR5 →
Q56VR3	—	0.990	Q56VR3 →
P98072	—	0.990	P98072 →
Q6IE64	—	0.989	Q6IE64 →
Q5E9Z2	—	0.989	Q5E9Z2 →
Q9GLP2	—	0.989	Q9GLP2 →
Q63207	—	0.989	Q63207 →
Q58L95	—	0.989	Q58L95 →